Amarin to Present at the 31st Annual J.P. Morgan Healthcare Conference

Amarin to Present at the 31st Annual J.P. Morgan Healthcare Conference

BEDMINSTER, N.J., and DUBLIN, Ireland, Jan. 2, 2013 (GLOBE NEWSWIRE) -- Amarin
Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health, announced that Joseph Zakrzewski, Amarin's Chairman and Chief
Executive Officer, is scheduled to present a company update at the 31^st
Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2013, at 11:30
a.m. PT. This conference will be held at the Westin St. Francis Hotel in San
Francisco, California.

A live audio webcast of the presentation will be available at:

http://jpmorgan.metameetings.com/webcasts/healthcare13/directlink?ticker=AMRN

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent
ethyl),Amarin'sfirstFDAapproved product, is a patented, ultra pure omega-3
fatty acid product comprising not less than 96%EPA.For more information
about Vascepa visit www.vascepa.com. For more information about Amarin visit
www.amarincorp.com.

The Amarin Corporation plc logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=13817

CONTACT: Stephen D. Schultz
         Senior Director, Investor Relations and
         Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.